Replicate design Vienna waltz [RSABE / ABEL]

posted by d_labes  – Berlin, Germany, 2011-04-28 10:54 (5536 d 16:10 ago) – Posting: # 6960
Views: 11,197

Dear Helmut, dear Andrew!

❝ Well, I'm not sure whether the model makes sense, but it's somehow in line with EMA's simplifications. Test treatments are ignored, as is the fact that the first and second administrations of the reference occurred in different periods in sequences 1/2.


What about recoding the treatments to T1, T2 and R1, R2 (numbers are Helmut's occasions or replicates) and evaluating the data as a 4x4 crossover with 2 sequences?

But which model ever, we make the assumption that the replicates are not the (random) result of the same formulation given at two occasions to the same subject, but something different. And that is to me not justifiable. Which effects should induce such a behaviour that we could separate the effects of the replicates? :lookaround:
To me a point estimate R2/R1 different from =1 does not make sense therefore.

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
120 visitors (0 registered, 120 guests [including 27 identified bots]).
Forum time: 03:05 CEST (Europe/Vienna)

The great tragedy of Science – the slaying
of a beautiful hypothesis by an ugly fact.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5